WO2013040242A3 - Dermal filler compositions for fine line treatment - Google Patents

Dermal filler compositions for fine line treatment Download PDF

Info

Publication number
WO2013040242A3
WO2013040242A3 PCT/US2012/055211 US2012055211W WO2013040242A3 WO 2013040242 A3 WO2013040242 A3 WO 2013040242A3 US 2012055211 W US2012055211 W US 2012055211W WO 2013040242 A3 WO2013040242 A3 WO 2013040242A3
Authority
WO
WIPO (PCT)
Prior art keywords
dermal filler
filler compositions
fine line
line treatment
compositions
Prior art date
Application number
PCT/US2012/055211
Other languages
French (fr)
Other versions
WO2013040242A2 (en
Inventor
Gabriel N. NJIKANG
Xiaojie Yu
Futian Liu
Sumit Paliwal
Nicholas J. Manesis
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/052125 external-priority patent/WO2013028904A2/en
Priority to KR1020217032224A priority Critical patent/KR20210125119A/en
Priority to JP2014530798A priority patent/JP6125509B2/en
Priority to CN201280055657.7A priority patent/CN104105474B/en
Priority to KR1020227001920A priority patent/KR20220013588A/en
Priority to KR1020147009782A priority patent/KR102161861B1/en
Priority to AU2012308503A priority patent/AU2012308503B2/en
Priority to EP12769798.5A priority patent/EP2755630A2/en
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Priority to RU2014113663A priority patent/RU2626513C2/en
Priority to KR1020207027527A priority patent/KR20200116168A/en
Priority to CA2848833A priority patent/CA2848833C/en
Publication of WO2013040242A2 publication Critical patent/WO2013040242A2/en
Publication of WO2013040242A3 publication Critical patent/WO2013040242A3/en
Priority to HK14111615.6A priority patent/HK1198124A1/en
Priority to AU2015255254A priority patent/AU2015255254B2/en
Priority to AU2017236004A priority patent/AU2017236004A1/en
Priority to AU2019203660A priority patent/AU2019203660B2/en
Priority to AU2021200516A priority patent/AU2021200516B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/505—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.
PCT/US2012/055211 2011-09-14 2012-09-13 Dermal filler compositions for fine line treatment WO2013040242A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
RU2014113663A RU2626513C2 (en) 2011-09-14 2012-09-13 Dermal filler composition for small wrinkles treating
KR1020207027527A KR20200116168A (en) 2011-09-14 2012-09-13 Dermal filler compositions for fine line treatment
JP2014530798A JP6125509B2 (en) 2011-09-14 2012-09-13 Dermal filler composition comprising an antioxidant
CA2848833A CA2848833C (en) 2011-09-14 2012-09-13 Ascorbate modified crosslinked hyaluronic acid dermal filler compositions that exhibit reduced tyndall effect
KR1020147009782A KR102161861B1 (en) 2011-09-14 2012-09-13 Dermal filler compositions for fine line treatment
AU2012308503A AU2012308503B2 (en) 2011-09-14 2012-09-13 Dermal filler compositions for fine line treatment
EP12769798.5A EP2755630A2 (en) 2011-09-14 2012-09-13 Dermal filler compositions for fine line treatment
KR1020217032224A KR20210125119A (en) 2011-09-14 2012-09-13 Dermal filler compositions for fine line treatment
KR1020227001920A KR20220013588A (en) 2011-09-14 2012-09-13 Dermal filler compositions for fine line treatment
CN201280055657.7A CN104105474B (en) 2011-09-14 2012-09-13 Dermal augmentation agent composition for microgroove treatment
HK14111615.6A HK1198124A1 (en) 2011-09-14 2014-11-17 Dermal filler compositions for fine line treatment
AU2015255254A AU2015255254B2 (en) 2011-09-14 2015-11-12 Dermal filler compositions for fine line treatment
AU2017236004A AU2017236004A1 (en) 2011-09-14 2017-09-29 Dermal filler compositions for fine line treatment
AU2019203660A AU2019203660B2 (en) 2011-09-14 2019-05-24 Dermal filler compositions for fine line treatment
AU2021200516A AU2021200516B2 (en) 2011-09-14 2021-01-28 Dermal filler compositions for fine line treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161534780P 2011-09-14 2011-09-14
US61/534,780 2011-09-14
PCT/US2012/052125 WO2013028904A2 (en) 2011-08-25 2012-08-23 Dermal filler compositions including antioxidants
USPCT/US2012/052125 2012-08-23

Publications (2)

Publication Number Publication Date
WO2013040242A2 WO2013040242A2 (en) 2013-03-21
WO2013040242A3 true WO2013040242A3 (en) 2014-03-13

Family

ID=47883970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/055211 WO2013040242A2 (en) 2011-09-14 2012-09-13 Dermal filler compositions for fine line treatment

Country Status (9)

Country Link
EP (1) EP2755630A2 (en)
JP (4) JP6125509B2 (en)
KR (4) KR20200116168A (en)
CN (2) CN104105474B (en)
AU (1) AU2012308503B2 (en)
CA (1) CA2848833C (en)
HK (1) HK1198124A1 (en)
RU (1) RU2626513C2 (en)
WO (1) WO2013040242A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
EP2484387A1 (en) 2011-02-03 2012-08-08 Q-Med AB Hyaluronic acid composition
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
KR20200116168A (en) * 2011-09-14 2020-10-08 알러간, 인코포레이티드 Dermal filler compositions for fine line treatment
HUE050947T2 (en) * 2011-12-08 2021-01-28 Allergan Ind Sas Dermal filler compositions
US20140315828A1 (en) 2013-04-22 2014-10-23 Allergan, Inc. Cross-linked silk-hyaluronic acid compositions
US20160074519A1 (en) * 2013-04-25 2016-03-17 Aluron Biopharma Inc. Crosslinked hyaluronic acid compositions
WO2016128783A1 (en) * 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
EP3653232A1 (en) * 2015-02-13 2020-05-20 Allergan Industrie, SAS Implants for sculpting, augmenting or correcting facial features such as the chin
EP3475312B1 (en) * 2016-06-23 2020-05-27 Galderma S.A. Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
EP3503841A4 (en) 2016-08-24 2020-04-22 Allergan, Inc. Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation
WO2018231718A1 (en) 2017-06-12 2018-12-20 Advanced Aesthetic Technologies, Inc. Dermal filler
US20230190997A1 (en) 2017-06-26 2023-06-22 Evolved By Nature, Inc. Silk-hyaluronic acid based tissue filers and methods of using the same
SG11201913229PA (en) * 2017-06-26 2020-01-30 Evolved By Nature Inc Silk-hyaluronic acid based tissue fillers and methods of using the same
CA3069968A1 (en) * 2017-07-19 2019-01-24 Dentsply Sirona Inc. Water-soluble hydrogel-based dental composition and methods of making and using same
CN111918640A (en) * 2017-12-29 2020-11-10 马特克斯拉比有限公司 Method for producing filler having hyaluronic acid group
KR101967153B1 (en) 2018-04-04 2019-04-09 윤성준 The material composition of the filler improving wrinkles, atrophic scars and other skin deficits
MA52880A (en) * 2018-06-15 2021-09-22 Croma Pharma Ges M B H HYDROGEL COMPOSITION CONTAINING A CROSS-LINKED POLYMER
IT201900006929A1 (en) * 2019-05-16 2020-11-16 Giuliani Spa KIT FOR AESTHETIC SKIN TREATMENT
CN110467689A (en) * 2019-09-09 2019-11-19 山东众山生物科技有限公司 A kind of derivatives of hyaluronic acids and preparation method thereof
CN110907370A (en) * 2019-12-04 2020-03-24 桂林理工大学 Universal ultra-sensitive chemical and biological colorimetric sensing method
US20230040919A1 (en) * 2019-12-26 2023-02-09 Allergan, Inc. Crosslinked ha-collagen hydrogels as dermal fillers
CN111249172A (en) * 2020-01-15 2020-06-09 陈勇 Beauty injection gel and preparation method thereof
TW202333793A (en) 2022-01-11 2023-09-01 義大利商Ｇｐｑ有限公司 New hyaluronic acid derivatives as innovative fillers
WO2024055132A1 (en) * 2022-09-12 2024-03-21 Universidad De Talca Method for the synthesis of a branched copolymer of hyaluronic acid and poly(lactic-co-glycolic) acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
KR100721752B1 (en) * 2000-01-24 2007-05-25 쿠라레 메디카루 가부시키가이샤 Water-swellable polymer gel and process for preparing the same
IT1317091B1 (en) * 2000-02-08 2003-05-26 S F I R Societa Fondaria Ind R CROSS-LINKED HYALURONIC ACID GEL WITH B-FUNCTIONAL L-AMINO ACIDS.
FR2811996B1 (en) 2000-07-19 2003-08-08 Corneal Ind CROSS-LINKING OF POLYSACCHARIDE (S), PREPARATION OF HYDROGEL (S); POLYSACCHARIDE (S) AND HYDROGEL (S) OBTAINED, THEIR USES
EP1592715A1 (en) * 2003-01-31 2005-11-09 Biosphere S.p.A. Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters
WO2004073759A1 (en) 2003-02-19 2004-09-02 Aventis Pharmaceuticals Holdings Inc. Composition and method for intradermal soft tissue augmentation
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
US8124120B2 (en) * 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
WO2005066215A1 (en) * 2003-12-30 2005-07-21 Genzyme Corporation Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use
FR2865737B1 (en) * 2004-02-03 2006-03-31 Anteis Sa BIOCOMPATIBLE RETICLE GEL
EP1750769B1 (en) * 2004-05-20 2013-01-23 Mentor Worldwide LLC Methods for making injectable polymer hydrogels
FR2873379B1 (en) * 2004-07-23 2008-05-16 Jerome Asius PROCESS FOR THE PREPARATION OF RETICULATED HYALURONIC ACID, RETICULATED HYALURONIC ACID WHICH CAN BE OBTAINED BY THIS METHOD, IMPLANT CONTAINING THE RETICULATED HYALURONIC ACID, AND USE THEREOF
FR2878444B1 (en) 2004-11-30 2008-04-25 Corneal Ind Soc Par Actions Si VISCOELASTIC SOLUTIONS COMPRISING SODIUM HYALURONATE AND HYDROXYPROPYLMETHYLCELLULOSE, PREPARATION AND USES
WO2007035296A2 (en) * 2005-09-15 2007-03-29 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
JP2009528438A (en) * 2006-02-28 2009-08-06 ノボザイムス バイオポリマー アクティーゼルスカブ Hyaluronic acid derivatives
CN1837265A (en) * 2006-04-25 2006-09-27 江南大学 Process for composite modification of hyaluronic acid and carboxymethyl cellulose
CN100417666C (en) * 2006-09-07 2008-09-10 重庆大学 Lysine-chitosan resin and preparation method thereof
FR2908415B1 (en) * 2006-11-10 2009-01-23 Abr Dev Sarl RETICULATED HYALURONIC ACID AND PROCESS FOR PREPARING THE SAME
FR2909560B1 (en) * 2006-12-06 2012-12-28 Fabre Pierre Dermo Cosmetique HYALURONIC ACID GEL FOR INTRADERMAL INJECTION
FR2918377B1 (en) * 2007-07-05 2010-10-08 Estelle Piron CO-RETICLE GEL OF POLYSACCHARIDES
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
CA2706183A1 (en) * 2007-12-21 2009-07-02 Encecor Ab Cross-linked hydrogel containing an active substance
KR20090110090A (en) * 2008-04-17 2009-10-21 엘지전자 주식회사 Synthesis method for indium selenide nanoparticles by ultrasonic waves and a compound semiconductor solar cell comprising the said
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
CN101961344A (en) * 2009-07-23 2011-02-02 山东省生物药物研究院 Drug composite and application thereof
IT1395392B1 (en) * 2009-08-27 2012-09-14 Fidia Farmaceutici VISCOELASTIC FROSTS LIKE NEW FILLERS
EP3037102A1 (en) * 2009-11-23 2016-06-29 Stephen F. Olmstead Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
US20110172180A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9149422B2 (en) * 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
KR20200116168A (en) * 2011-09-14 2020-10-08 알러간, 인코포레이티드 Dermal filler compositions for fine line treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARK DJ ET AL: "IN VITRO EVALUATION OF CONJUGATED HYALURONIC ACID WITH ASCORBIC ACID", JOURNAL OF BONE AND JOINT SURGERY,, vol. 92-B, no. SUPP I, 1 January 2010 (2010-01-01), pages 115, XP002706399 *

Also Published As

Publication number Publication date
AU2012308503B2 (en) 2015-08-13
RU2626513C2 (en) 2017-07-28
JP6125509B2 (en) 2017-05-10
JP2019058692A (en) 2019-04-18
RU2014113663A (en) 2015-10-20
KR20220013588A (en) 2022-02-04
AU2012308503A1 (en) 2014-04-03
CN104105474A (en) 2014-10-15
JP2021100603A (en) 2021-07-08
CA2848833C (en) 2017-04-04
CA2848833A1 (en) 2013-03-21
KR102161861B1 (en) 2020-10-26
EP2755630A2 (en) 2014-07-23
KR20140096028A (en) 2014-08-04
KR20210125119A (en) 2021-10-15
KR20200116168A (en) 2020-10-08
CN104105474B (en) 2018-04-06
HK1198124A1 (en) 2015-03-13
JP2014526342A (en) 2014-10-06
WO2013040242A2 (en) 2013-03-21
JP2017140433A (en) 2017-08-17
CN108379112A (en) 2018-08-10

Similar Documents

Publication Publication Date Title
WO2013040242A3 (en) Dermal filler compositions for fine line treatment
JOP20180102B1 (en) Pharmaceutical composition
WO2012167079A3 (en) Dermal filler compositions including antioxidants
MX2018016021A (en) Compositions and methods comprising a lipolytic enzyme variant.
EP3129494A4 (en) Hydrogel compositions for use in promoting tubulogenesis
MX352892B (en) Yeast-muc1 immunotherapeutic compositions and uses thereof.
EP2681268B8 (en) Organosiloxane compositions
MX2012015188A (en) Controlled release compositions with reduced food effect.
WO2013086024A3 (en) Dermal filler compositions
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP2872151A4 (en) Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases
MY169328A (en) Compositions for the treatment of dry eye
IN2014DN08299A (en)
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
WO2013120022A3 (en) Treatment of hypoglycemia
WO2012017321A3 (en) Treatment for dyslipidemia
MX359181B (en) Collagen hydrolysate and use thereof.
EP3076952A4 (en) Composition for oral delivery of bioactive agents
IN2014DN00254A (en)
MY165088A (en) Pharmaceutical compositions comprising alisporivir
UA117567C2 (en) Galactagogue compositions based on phosphatidylserine
GB201003336D0 (en) Fungal treatment compositions
MX2015005846A (en) Block copolymers for tooth enamel protection.
WO2014022475A8 (en) Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
EP2569327A4 (en) Eif4e binding peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12769798

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014530798

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2848833

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2012308503

Country of ref document: AU

Date of ref document: 20120913

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147009782

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2014113663

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12769798

Country of ref document: EP

Kind code of ref document: A2